MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte ...
Hologic, Inc. HOLX recently expanded its Global Access Initiative (“GAI”) with the addition of the Aptima SARS-CoV-2 assay. The GAI’s all-inclusive pricing structure is anticipated to make the Aptima ...
Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of ...
Hologic’s HOLX fully automated, high-throughput Panther platform remains the foundation of its molecular diagnostics business. The Panther Fusion module, a 2016 addition to the base system, provides ...
New Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays deliver tailored, actionable diagnostic results to support fast and informed patient care A variety of complex factors, ...
Hologic HOLX has highlighted the role of its Panther Fusion platform in supporting the future growth of its Diagnostics business. Fusion is an add-on module to the base Panther system, providing a ...
Hologic has secured a $119M contract to increase production capacity for diagnostic kits and test consumables in support of government efforts to sustain the U.S. industrial base through the ...
Thanks to the pandemic, Hologic delivered an astounding fiscal first quarter that featured organic growth of 104% year over year, driven by molecular diagnostics. We’re modestly raising our fair value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback